Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Results 1 - 20 of 136 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar ladynutz (38.26) Submitted: 7/7/2015 9:49:29 PM : Outperform Start Price: $34.61 MYGN Score: +5.09

I am a firm beliver this sector has not even begun to hit it's stride.

Recs

1
Member Avatar stereotyp72 (45.89) Submitted: 1/13/2015 10:11:35 AM : Outperform Start Price: $39.00 MYGN Score: -13.01

Short Ratio is unusual high.

Recs

1
Member Avatar Doggylad (< 20) Submitted: 8/1/2014 10:22:52 AM : Underperform Start Price: $37.29 MYGN Score: +10.05

It relies on BRCA testing, which will see extreme price pressure from payors

Recs

2
Member Avatar jpat34721 (< 20) Submitted: 5/6/2014 9:44:48 PM : Outperform Start Price: $39.02 MYGN Score: -17.75

Great company in a high growth sector ( diagnostics )

Recs

0
Member Avatar OKwarrior (23.35) Submitted: 3/25/2014 6:14:06 PM : Outperform Start Price: $35.39 MYGN Score: -8.43

biotech w/ profits!! This company has minimal debt & phenomenal ROIC and ROE. They are currently on a pullback, but it is time to jump in!

Recs

0
Member Avatar EdFromOhio (21.68) Submitted: 2/26/2014 4:16:38 PM : Underperform Start Price: $37.21 MYGN Score: +14.92

Too high, too fast.

Recs

0
Member Avatar collinriley2 (< 20) Submitted: 2/26/2014 2:54:24 PM : Outperform Start Price: $37.53 MYGN Score: -15.64

I have some shares.

Recs

0
Member Avatar neezeeann (< 20) Submitted: 2/10/2014 2:44:52 AM : Outperform Start Price: $32.14 MYGN Score: -2.58

I just have a feeling. This is going to 60 a share in 3 years. Amazing product line until the patents run out and then business will become competitive. Revs increasing setting up for the perfect storm on performance

Recs

0
Member Avatar modestus1 (< 20) Submitted: 2/5/2014 3:10:25 PM : Outperform Start Price: $31.98 MYGN Score: -4.95

Bought rival. Beat estimates.

Recs

1
Member Avatar mario1234 (< 20) Submitted: 1/18/2014 5:43:49 AM : Outperform Start Price: $24.86 MYGN Score: +33.65

Sold fundamentals. Why do doctors want to know your family history? To provide preventive guidance. The diagnostic tests this company provides quantify this information in a very specific way. Even though Medicare will no longer pay for these tests it in the younger patients not the elderly that are the target market. Affordable Care Act. In time the insurance companies will embrace this concept if it proves to cut cost of healthcare. The market over reacted to the court ruling. 47% of float shorted. Huge short squeeze on any good news.

Recs

1
Member Avatar oncqueen (68.38) Submitted: 12/31/2013 10:09:27 AM : Outperform Start Price: $20.76 MYGN Score: +62.21

I think the huge dip is an overreaction. I order 5 of these a month in my practice, and while there are others coming up with similar tests, there will be a lag time.

Recs

1
Member Avatar DrLinks (< 20) Submitted: 7/20/2013 11:26:09 PM : Outperform Start Price: $31.25 MYGN Score: -6.38

Massive Diagnostics Rx Cmpany!

Recs

0
Member Avatar VEGFR2 (< 20) Submitted: 6/19/2013 3:26:54 PM : Underperform Start Price: $25.95 MYGN Score: -13.68

BRCA1/2 testing competition from other companies that will utilize next gen sequencing techniques. Supreme court ruling eliminates Myriad's monopoly

Recs

0
Member Avatar jesterisdead (21.37) Submitted: 6/14/2013 2:11:51 AM : Underperform Start Price: $29.22 MYGN Score: +2.22

Lost BRCA1/BRCA2 patents. They are going down.

Recs

0
Member Avatar topsav1 (< 20) Submitted: 5/18/2013 5:27:15 PM : Outperform Start Price: $32.87 MYGN Score: -14.05

obama's buddies

Recs

0
Member Avatar nickutah1 (39.79) Submitted: 5/15/2013 8:06:46 PM : Outperform Start Price: $33.89 MYGN Score: -18.13

The Affordable Care Act and publicity over A Jolie's surgery due to BRACA genes will boost sales of the BRACA genetics test, of which Myriad is the only producer.

Recs

0
Member Avatar awallejr (59.52) Submitted: 2/9/2013 9:19:57 PM : Outperform Start Price: $26.37 MYGN Score: +0.85

Porte and ZZ.

Recs

0
Member Avatar SharpNJ104 (50.64) Submitted: 4/16/2012 6:02:57 PM : Outperform Start Price: $24.07 MYGN Score: +0.21

Great product without the downside risks of drugs. Increasing contracts with other drug companies for use of their genetic tests for the drug co's drug trials. The future of medicine is personalized based on each inidividual.

Recs

2
Member Avatar shu78 (< 20) Submitted: 10/12/2011 10:08:13 PM : Outperform Start Price: $20.17 MYGN Score: +6.93

Well run company with minimal debt. All star board of directors. The future will eventually be preventative medicine, and this company is an early mover in that field.

Recs

0
Member Avatar sellerorbuyer (< 20) Submitted: 1/14/2011 10:44:39 AM : Underperform Start Price: $21.58 MYGN Score: -6.92

so much competitors

Featured Broker Partners